Market Place
Sourcing Support
Windtree Therapeutics Enhances Istaroxime Patent Portfolio
14 Nov 2025 //
GLOBENEWSWIRE
Windtree To Receive $7.5M From Recent Termination Agreement
13 Nov 2025 //
GLOBENEWSWIRE
Windtree Secures $520M for BNB Cryptocurrency Strategy
24 Jul 2025 //
GLOBENEWSWIRE
Windtree`s Istaroxime Phase 2 Study Hits Enrollment Target
30 Jun 2025 //
GLOBENEWSWIRE
Windtree Announces Istaroxime Phase 2 SeisMi C B Study
16 Jun 2025 //
GLOBENEWSWIRE
Windtree gets offer for preclinical oncology drug
11 Jun 2025 //
GLOBENEWSWIRE
Windtree Announces Plan for Cryptocurrency Treasury Policy
03 Jun 2025 //
GLOBENEWSWIRE
Windtree Therapeutics to Release Istaroxime Study Interim Results
22 May 2025 //
GLOBENEWSWIRE
Windtree Shares Istaroxime Data at ESC Heart Failure Conference
19 May 2025 //
GLOBENEWSWIRE
Windtree Therapeutics Presents Preclinical Data on Istaroxime
12 May 2025 //
GLOBENEWSWIRE
Windtree announces Istaroxime exclusivity and IP strategy for US
06 May 2025 //
GLOBENEWSWIRE
Windtree Unveils Deal to Boost Revenue, Advance Drug Pipeline
01 May 2025 //
GLOBENEWSWIRE
Windtree Therapeutics Reports 2024 Financial Results & Updates
15 Apr 2025 //
GLOBENEWSWIRE
Windtree to Partner with Small Biotech for FDA Approved Product
20 Mar 2025 //
GLOBENEWSWIRE
Windtree Secures Istaroxime Patent Allowance For Acute Heart Failure
04 Mar 2025 //
GLOBENEWSWIRE
Windtree files patent for istaroxime in India
27 Feb 2025 //
GLOBENEWSWIRE
Windtree Therapeutics, Inc. Announces Reverse Stock Split
18 Feb 2025 //
GLOBENEWSWIRE
Windtree To Present Istaroxime Data At Heart Failure Conference
12 Feb 2025 //
GLOBENEWSWIRE
Windtree Secures Important Japanese Patent For Cancer Research
17 Jan 2025 //
GLOBENEWSWIRE
Windtree Announces Addition of Leanne Kelly to Board of Directors
13 Jan 2025 //
GLOBENEWSWIRE
Windtree Adopts Strategy To Acquire FDA Assets, Advance Pipeline
08 Jan 2025 //
GLOBENEWSWIRE
Windtree Files New Istaroxime Patent for Myocardial Arrhythmia
09 Dec 2024 //
GLOBENEWSWIRE
Windtree Partners for Potential Strategic Deal in Cardiogenic Shock
04 Dec 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Q3 2024 Financial Results & Updates
27 Nov 2024 //
GLOBENEWSWIRE
Windtree Announces Leadership Transition Plan
14 Nov 2024 //
GLOBENEWSWIRE
Windtree Expands Patents with Hong Kong Istaroxime Patent Issuance
04 Nov 2024 //
GLOBENEWSWIRE
Windtree Therapeutic Initiates Seismic C Study in Cardiogenic Shock
30 Oct 2024 //
GLOBENEWSWIRE
Windtree Announces Istaroxime Patent Filings Worldwide
23 Oct 2024 //
GLOBENEWSWIRE
Windtree To Present at the ThinkEquity Conference on October 30th
21 Oct 2024 //
GLOBENEWSWIRE
Windtree Expands Patents With Istaroxime Patent Issued In Japan
17 Oct 2024 //
GLOBENEWSWIRE
Windtree Announces Publication Of Istaroxime Phase 2b Design
09 Oct 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Announces Virtual Investor Day Presentation
26 Sep 2024 //
GLOBENEWSWIRE
Windtree’s shock med raises blood pressure in latest phase 2 win
26 Sep 2024 //
BIOSPACE
Windtree Completes Enrollment For Istaroxime Study
04 Sep 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Q2 2024 Results And Business Updates
20 Aug 2024 //
GLOBENEWSWIRE
Windtree Announces New Additions and Changes to Its Board of Directors
14 Aug 2024 //
GLOBENEWSWIRE
